Stock Market Reviews

PACB (Pacific Biosciences of California, Inc.) News

Get the latest news, insights, and market updates on PACB (Pacific Biosciences of California, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Why PacBio (PACB) Stock Is Up Today
  Shares of genomics company Pacific Biosciences of California (NASDAQ:PACB) jumped 4.5% in the afternoon session after the stock's positive momentum continued as the company announced advances in its RNA sequencing technology for lung cancer research. The stock’s climb continued a recent trend, following a 4.04% gain during the last trading day. The move extended a strong performance over the previous two weeks, in which the stock rose by more than 47%. Overall sentiment from analysts also remain
  Dec 3, 2025 - $PACB
• PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
  MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at le
  Nov 28, 2025 - $PACB
• How Recent Moves Are Rewriting the Story for PacBio Amid Shifting Analyst Sentiment
  The consensus analyst price target for Pacific Biosciences of California has ticked up slightly from $2.23 to $2.25, signaling a modest increase in expectations for the company’s fair value. This shift is underpinned by ongoing revenue growth and a markedly lower discount rate, which reflects improved perceptions of the company’s risk profile and strengthens confidence among investors. Stay tuned to discover how you can keep ahead of further updates to the evolving narrative surrounding...
  Nov 27, 2025 - $PACB
• PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers, making them crucial for insurers focused on the
  Nov 24, 2025 - $PACB
• Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025 - $PACB
• Top 3 Genomics Stocks to Consider for Your Portfolio
  Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
  Nov 18, 2025 - $PACB
• 3 Healthcare Stocks We Approach with Caution
  From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.5% has lagged the S&P 500’s 13% climb.
  Nov 18, 2025 - $PACB
• 3 of Wall Street’s Favorite Stocks We Approach with Caution
  Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
  Nov 14, 2025 - $PACB
• Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
  Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
  Nov 13, 2025 - $PACB
• PacBio to Present at Upcoming Investor Conferences
  MENLO PARK, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Wolfe Research Healthcare Conference 2025 in New York, NY Fireside chat on Tuesday, November 18 at 8:40 AM ET Jefferies Global Healthcare Conference in London, UK Hosting 1x1 meetings only on Wednesday, November 19 Stephens Annual Investment Conf
  Nov 13, 2025 - $PACB